Product Details

Act Ezetimibe

Ezetimibe
10 mg
Tablet


DIN/PIN/NPN

02414716

Manufacturer

Actavis Pharma Company

Formulary Listing Date

2014-11-27  

Unit Price

0.1811

Amount MOH Pays

0.1811

Coverage Status

Limited Use Product Chronic-Use Medication

ODB Formulary Therapeutic Classification

Therapeutic Note

NO

ATC Code

C10AX09

Interchangeable Products

DIN/ PIN/ NPN Brand name Unit Price Amount MOH pays
02354101 Teva-Ezetimibe 0.1811 0.1811
02416778 Sandoz Ezetimibe 0.1811 0.1811
02419548 Ran-Ezetimibe 0.1811 0.1811
02416409 PMS-Ezetimibe 0.1811 0.1811
02481669 NRA-Ezetimibe 0.1811 0.1811
02423243 Mint-Ezetimibe 0.1811 0.1811
02467437 M-Ezetimibe 0.1811 0.1811
02422662 Mar-Ezetimibe 0.1811 0.1811
02423235 Jamp-Ezetimibe 0.1811 0.1811
02460750 GLN-Ezetimibe 0.1811 0.1811
02247521 Ezetrol 2.0415 0.1811
02431300 Ezetimibe 0.1811 0.1811
02429659 Ezetimibe 0.1811 0.1811
02469286 Auro-Ezetimibe 0.1811 0.1811
02427826 Apo-Ezetimibe 0.1811 0.1811
02475898 AG-Ezetimibe 0.1811 0.1811
02414716 Act Ezetimibe 0.1811 0.1811
02425610 Ach-Ezetimibe 0.1811 0.1811
02536420 NRA-Ezetimibe Tablets 0.1811 0.1811
 

LU Clinical Criteria

LU Code Auth. Period Clinical Criteria
380 Indefinite

For use in combination with a HMG-CoA reductase inhibitor ('statin') in patients with hypercholesterolemia who have not reached target LDL levels despite the use of maximally tolerated doses.

381 Indefinite

For use as monotherapy in the management of hypercholesterolemia in patients who are intolerant to HMG-CoA reductase inhibitors or where HMG-CoA reductase inhibitors are contraindicated.

 

EAP Criteria

NO

Product Monograph

View Monograph